1 Min Read
March 13 (Reuters) - BioTime Inc-
* BioTime expands opregen® clinical trial in dry-amd with opening of first us sites
* Anticipate enrolling and treating U.S.-based patients by end of Q2 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.